Form D · Pharmaceuticals
TIXiMED, Inc.
Birmingham, AL · CIK 0002043713
Offering snapshot reported Nov 5, 2024 · SEC filing
- Reported sold
- $550K Offering amount: $550K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 15, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 5, 2024 | Initial | $550,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-528704
Source: Form D, filed Nov 5, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas Michael Goodrich Ii | Director, Executive |
| Aneth Shalev | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1927 1 St Avenue North Sixth Floor
Birmingham, AL, 35203
Birmingham, AL, 35203